Engineering the future
of RNAi-based medicine

Leading the next generation of RNAi therapeutics

Unlocking the full potential of RNAi

Founded by pioneering executives and scientists in RNAi, City Therapeutics™ is harnessing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines.

City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

A vast opportunity ahead

siRNA engineering platform to deliver disruptive medicines

RNAi-based medicines possess high biological specificity, work upstream of other classes of drugs by directly targeting and degrading messenger RNA to silence gene expression and block protein production, and have the potential to address a wide range of diseases.

Leveraging next-generation trigger molecule engineering, City Therapeutics is building a sustainable product engine of RNAi-based medicines to make a significant impact for patients across multiple therapeutic areas. These include prevalent disease indications where RNAi therapeutics have clear advantages over other modalities such as small molecules and antibodies.

Better molecules

Creating novel RNAi trigger molecules with improved potency and foundational intellectual property.

City is designing various trigger molecules including those with smaller size, novel cleavage mechanisms, less negative charge and improved potency, efficiency and specificity. Examples include cleavage-inducing tiny (city) RNAs that cleave target messenger RNA through distinct proteins to silence gene expression.

Better delivery

Developing purposely tailored targeting ligands to reach more cells and tissue types.

These novel targeting ligands enable robust delivery of RNAi therapeutics to treat a broader range of human diseases than what is possible with the current generation of RNAi-based medicines.

Better targets

Leveraging the latest advancements and insights in human genetics.

We are addressing both novel and validated therapeutic targets and optimizing clinical development to deliver the greatest impact for patients.

Building the industry’s next leading RNAi company

We are led by the creators of the first generation of RNAi therapeutics, with a bold new vision for the future. We are advancing a pipeline of RNAi-based medicines to drive sustainable growth and make a significant impact for patients across multiple disease indications.

Join us in crafting the future of RNAi therapeutics.